| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d0d2dd1461efd3a53a38648d3270a0a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb5c69001deab4e3fe10a5d13b2e723c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c14f2df01757096138870ab2d1db54ad |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-141
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2020-06-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e2aa7fa088b71526183756a0644bc51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e40a4791068db8de42e68990654e90ec |
| publicationDate |
2020-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020247675-A1 |
| titleOfInvention |
Methods for attenuating viral infection and for treating lung injury |
| abstract |
The described invention provides compositions and methods for treating a susceptible subject at risk of pulmonary complications of an acute lung injury caused by a severe infection with a respiratory virus and for restoring lung function to donor lungs. The methods include administering a therapeutic amount of a pharmaceutical composition comprising extracellular vesicles (EVs) comprising one or more miRNAs and a pharmaceutically acceptable carrier. The population of EVs can be derived from a patient who has recovered from an infection with the respiratory virus or has been exposed to anti-viral antibodies through treatment, can be derived from MSCs of a normal healthy individual, can be modified by a viral vector, or can be synthetic. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114685652-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113881692-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114113581-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114113581-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022143816-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114699430-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-116287476-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021216584-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022241475-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115125198-A |
| priorityDate |
2019-06-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |